152 related articles for article (PubMed ID: 23650051)
21. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
22. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
23. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.
Tamura A; Watanabe M; Saito H; Nakagawa H; Kamachi T; Okura I; Ishikawa T
Mol Pharmacol; 2006 Jul; 70(1):287-96. PubMed ID: 16608919
[TBL] [Abstract][Full Text] [Related]
24. Aberrantly elevated redox sensing factor Nrf2 promotes cancer stem cell survival via enhanced transcriptional regulation of ABCG2 and Bcl-2/Bmi-1 genes.
Jia Y; Chen J; Zhu H; Jia ZH; Cui MH
Oncol Rep; 2015 Nov; 34(5):2296-304. PubMed ID: 26324021
[TBL] [Abstract][Full Text] [Related]
25. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways.
Chen Q; Li W; Wan Y; Xia X; Wu Q; Chen Y; Lai Z; Yu C; Li W
Hepatology; 2012 Jun; 55(6):1820-9. PubMed ID: 22213475
[TBL] [Abstract][Full Text] [Related]
26. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
27. Elevated Expression of Nrf-2 and ABCG2 Involved in Multi-drug Resistance of Lung Cancer SP Cells.
Yang B; Ma YF; Liu Y
Drug Res (Stuttg); 2015 Oct; 65(10):526-31. PubMed ID: 25368906
[TBL] [Abstract][Full Text] [Related]
28. Role of ABCG2/BCRP in biology and medicine.
Krishnamurthy P; Schuetz JD
Annu Rev Pharmacol Toxicol; 2006; 46():381-410. PubMed ID: 16402910
[TBL] [Abstract][Full Text] [Related]
29. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs.
Tamura A; Onishi Y; An R; Koshiba S; Wakabayashi K; Hoshijima K; Priebe W; Yoshida T; Kometani S; Matsubara T; Mikuriya K; Ishikawa T
Drug Metab Pharmacokinet; 2007 Dec; 22(6):428-40. PubMed ID: 18159130
[TBL] [Abstract][Full Text] [Related]
30. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy.
Robey RW; Steadman K; Polgar O; Bates SE
Cancer Biol Ther; 2005 Feb; 4(2):187-94. PubMed ID: 15684613
[TBL] [Abstract][Full Text] [Related]
31. ABCG2: determining its relevance in clinical drug resistance.
Robey RW; Polgar O; Deeken J; To KW; Bates SE
Cancer Metastasis Rev; 2007 Mar; 26(1):39-57. PubMed ID: 17323127
[TBL] [Abstract][Full Text] [Related]
32. The ABC transporter Abcg2/Bcrp: role in hypoxia mediated survival.
Krishnamurthy P; Schuetz JD
Biometals; 2005 Aug; 18(4):349-58. PubMed ID: 16158227
[TBL] [Abstract][Full Text] [Related]
33. ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy.
Palasuberniam P; Yang X; Kraus D; Jones P; Myers KA; Chen B
Sci Rep; 2015 Aug; 5():13298. PubMed ID: 26282350
[TBL] [Abstract][Full Text] [Related]
34. New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies.
Westover D; Li F
J Exp Clin Cancer Res; 2015 Dec; 34():159. PubMed ID: 26714461
[TBL] [Abstract][Full Text] [Related]
35. The role of ABCG2 and ABCB6 in porphyrin metabolism and cell survival.
Krishnamurthy P; Schuetz JD
Curr Pharm Biotechnol; 2011 Apr; 12(4):647-55. PubMed ID: 21118089
[TBL] [Abstract][Full Text] [Related]
36. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.
Furukawa T; Wakabayashi K; Tamura A; Nakagawa H; Morishima Y; Osawa Y; Ishikawa T
Pharm Res; 2009 Feb; 26(2):469-79. PubMed ID: 18958403
[TBL] [Abstract][Full Text] [Related]
37. The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression.
Jung KA; Choi BH; Kwak MK
Mol Pharmacol; 2015; 87(3):465-76. PubMed ID: 25534417
[TBL] [Abstract][Full Text] [Related]
38. The sensitivity of glioma cells to pyropheophorbide-αmethyl ester-mediated photodynamic therapy is enhanced by inhibiting ABCG2.
Pan L; Lin H; Tian S; Bai D; Kong Y; Yu L
Lasers Surg Med; 2017 Sep; 49(7):719-726. PubMed ID: 28370217
[TBL] [Abstract][Full Text] [Related]
39. NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression.
Kim EJ; Kim YJ; Lee HI; Jeong SH; Nam HJ; Cho JH
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629871
[TBL] [Abstract][Full Text] [Related]
40. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
